If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-17. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
At the same time, the volume of fish reaching inland markets such as Sanaʿa reportedly declined by more than half, while retail prices increased by roughly 30–40 percent. This combination of reduced supply and higher prices contributed also to the food insecurity problem. Moreover, the closure or partial shutdown of fish-processing plants, ice factories and related businesses led to thousands of job losses along the chain, with analysts noting how the sector may even experience further shocks, including the possibility of an oil spill in the Red Sea.
Organozinc chemistry is the science of compounds that contain carbon-zinc bonds, describing the physical properties, synthesis, and chemical reactions. Many organozinc compounds are commercially important. Among important applications are:
Clinton. In October 2002 at the International Symposium on Chromatography in London, Klaus Mosbach was presented the Martin Gold Medal, at the Royal Society, for the year 2000, by the Executive Committee of the Chromatographic Society. It was awarded him "in recognition of his major contributions to the field of separation science over many years". Previous recipients of this award are inter alia F. Regnier (1993), C. Horvath (1994) and W.H. Pirkle (1990). Mosbach published more than 537 peer reviewed scientific articles and reviews with an H-Index of 77. Mosbach wrote and edited four volumes of methods in enzymology series on Immobilized Enzymes, by Academic press (44,132,133,134). In addition he has received and applied for 84 patents.
=== Laminin G === The laminin globular (G) domain, also known as the LNS (Laminin-alpha, Neurexin and Sex hormone-binding globulin) domain, is on average 177 amino acids in length and can be found in one to six copies in various laminin family members as well as in a large number of other extracellular proteins. For example, all laminin alpha-chains have five laminin G domains, all collagen family proteins have one laminin G domain, the CNTNAP proteins have four laminin G domains, while neurexin 1 and 2 each hold six laminin G domains. On average, approximately one quarter of the proteins that hold laminin G domains is taken up by these laminin G domains themselves. The smallest laminin G domain can be found in one of the collagen proteins (COL24A1; 77 AA) and the largest domain in TSPEAR (219 AA). The exact function of the Laminin G domains has remained elusive, and a variety of binding functions has been ascribed to different Laminin G modules. For example, the laminin alpha1 and alpha2 chains each have five C-terminal laminin G domains, where only domains LG4 and LG5 contain binding sites for heparin, sulphatides and the cell surface receptor dystroglycan. Laminin G-containing proteins appear to have a wide variety of roles in cell adhesion, signalling, migration, assembly and differentiation.
Sources: en.wikipedia.org
Using stem-cell-derived GABAergic and glutamatergic neurons, as well as human APOE knock-in mice, researchers find that APOE2 neurons show lower DNA damage and greater resistance to genotoxic-stress-induced cellular senescence than APOE4 neurons, suggesting a possible mechanism for APOE2's association with reduced Alzheimer's disease risk. 11 May – A preprint reports the discovery of Ross 318 b, a candidate temperate super-Earth orbiting within the habitable zone of the nearby red dwarf Ross 318. Detected using radial velocity measurements from CARMENES and HIRES, the planet has a 39.6-day orbit, a minimum mass of 6.21 Earth masses, and shows no detectable transit in TESS photometry. 12 May – A study published in Frontiers in Earth Science reports isotopic evidence from helium and carbon in hydrothermal fluids from Zambia's Kafue Rift, suggesting early-stage rifting in the proposed Southwestern Rift of Africa. The findings indicate mantle-derived fluids reaching the surface and may support the existence of an emerging plate boundary capable of future continental separation. 26 May – A preprint reports the atomically precise mechanosynthesis of carbon structures on hydrogenated silicon using inverted-mode scanning tunneling microscopy (STM). Researchers demonstrate controlled donation of C2 units to pre-patterned reactive sites, repeated placement of carbon units, and stepwise formation of polyyne-like carbon chains through successive C–C bond formation, suggesting a possible route toward programmable atomically precise fabrication.
==== Immunohistochemistry Approaches ==== As an antibody technique, immunohistochemistry (IHC) allows for validating protein presence. It, and immunocytochemistry, allow for surveying the localization of proteases on a tissue or cellular scale respectively. It also can evaluate for the localization of cleavage products using monoclonal antibodies raised against neo-epitopes of cleavage sites produced by protease processing. Unfortunately, in addition to providing little functional information, IHC is also non-quantitative, making it an unappealing option for describing degradomics on system-wide scales.
=== Japan === Between 1992 and 1997, Japan's Ministry of International Trade and Industry sponsored a "New Hydrogen Energy (NHE)" program of US$20 million to research cold fusion. Announcing the end of the program in 1997, the director and one-time proponent of cold fusion research Hideo Ikegami stated "We couldn't achieve what was first claimed in terms of cold fusion. (...) We can't find any reason to propose more money for the coming year or for the future." In 1999 the Japan C-F Research Society was established to promote the independent research into cold fusion that continued in Japan. The society holds annual meetings. Perhaps the most famous Japanese cold fusion researcher was Yoshiaki Arata, from Osaka University, who claimed in a demonstration to produce excess heat when deuterium gas was introduced into a cell containing a mixture of palladium and zirconium oxide, a claim supported by fellow Japanese researcher Akira Kitamura of Kobe University and Michael McKubre at SRI.
Sources: en.wikipedia.org
restriction enzyme Also restriction endonuclease, restriction exonuclease, or restrictase. An endonuclease or exonuclease enzyme that recognizes and cleaves a nucleic acid molecule into fragments at or near specific recognition sequences known as restriction sites by breaking the phosphodiester bonds of the nucleic acid backbone. Restriction enzymes are naturally occurring in many organisms, but are also routinely used for artificial modification of DNA in laboratory techniques such as restriction cloning.
=== Density === The highest density of CNTs was achieved in 2013, grown on a conductive titanium-coated copper surface that was coated with co-catalysts cobalt and molybdenum at lower than typical temperatures of 450 °C. The tubes averaged a height of 380 nm and a mass density of 1.6 g cm−3. The material showed ohmic conductivity (lowest resistance ~22 kΩ).
==== Companion of the Order of the Bath (CB) ==== Military Rear Admiral Andrew Betton, , Royal Navy, C033663C. Rear Admiral James David Morley, Royal Navy, C034410Y Major General Kevin Mark Copsey, , 533047. Major General John Robert Mead, , 537468. Air Vice-Marshal Nigel James Colman, , Royal Air Force, 8304546T. Air Marshal Ian David Gale, , Royal Air Force, 8304212Q. Civil Ruth Léonie Hannant, Director General, Policy, Department for Culture, Media and Sport. For Public Service. Liam Cledwyn Laurence Smyth, Clerk of Legislation, House of Commons. For services to Parliament. Jonathan Marron, Director General, Office of Health Inequalities and Disparities, Department of Health and Social Care. For services to Public Health. Lee McDonough, Director General, Net Zero, Nuclear and International, Department for Energy Security and Net Zero. For services to Energy and Climate. Simon Millhouse, Ministry of Defence. For services to Defence. Neil Brendan O'Connor, , lately Director, Building Safety Programme, Department for Levelling Up, Housing and Communities. For services to Building Safety. Polly Theresa Payne, Director General, Policy, Department for Culture, Media and Sport. For Public Service. Sir Arthur Gareth Ludovic Emrys Rhys Williams, , Government Chief Commercial Officer, Cabinet Office. For Public Service. Kenneth Andrew Lyons Thomson, lately Director General, Scottish Government. For Public Service. Brendan Peter Threlfall, , Director General, Union and Windsor Framework, Cabinet Office. For Public Service. Dr Abigail Tierney, lately Director General, Home Office.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.